Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DES Makers, Hospitals Will Not Get Higher-Paying DRG In FY 2004 – Scully

This article was originally published in The Gray Sheet

Executive Summary

Competition provided by additional drug-eluting stent players in the U.S. ultimately will drive down pricing, making it unnecessary to further increase reimbursement for the technology in FY 2004, CMS Administrator Tom Scully asserted

You may also be interested in...



Drug-Coated Stent Competition Unlikely To Immediately Lower Prices – Cordis

The Centers for Medicare & Medicaid Services should increase the price difference between drug-eluting and bare-metal stents to $3,024 - $1,539 more than the rate suggested in the hospital IPPS proposed rule, according to Johnson & Johnson/Cordis

Drug-Coated Stent Competition Unlikely To Immediately Lower Prices – Cordis

The Centers for Medicare & Medicaid Services should increase the price difference between drug-eluting and bare-metal stents to $3,024 - $1,539 more than the rate suggested in the hospital IPPS proposed rule, according to Johnson & Johnson/Cordis

Guidant ICD, Stent Tactics Assuage Wall Street; Q1 Index Inches Up

Guidant allayed investor uncertainty over its future business strategy by winning a favorable MCAC reimbursement recommendation and executing a string of stent technology acquisitions, propelling the stock ahead 17.3% for the first quarter

UsernamePublicRestriction

Register

LL1121650

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel